Abelacimab获得FDA快速通道资格，用于房颤患者卒中预防丨心“药”闻

全球有四分之一的人死于血栓栓塞事件。尽管在过去60年间抗凝治疗取得了重要进展，但临床中仍然需要新的药物来预防卒中，同时需要这些药物具有更低的出血风险，尤其是对于老年人、肾功能或肝功能不全的患者、有出血史的患者。

信源：Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation. https://www.globenewswire.com/news-release/2022/09/08/2512472/0/en/Anthos-Therapeutics-Announces-that-Abelacimab-Has-Received-FDA-Fast-Track-Designation-for-the-Prevention-of-Stroke-and-Systemic-Embolism-in-Patients-with-Atrial-Fibrillation.html